Know Cancer

forgot password

Tumor Markers in Lung Cancer: DCAMLK-1LK-1: A Pilot Study

45 Years
Not Enrolling
Lung Cancer, Smoking

Thank you

Trial Information

Tumor Markers in Lung Cancer: DCAMLK-1LK-1: A Pilot Study

In the investigators' preliminary study DCAMKL1 antigen was detected not only in malignant
tissue, but also in BAL fluid from patients with benign lung disease. This suggests that
DCAMKL1 expression might be induced by smoking or benign lung diseases. To examine this
hypothesis, the investigators will compare DCAMLK1 expression in blood from patients with
lung cancer to controls who are current or former smokers with benign lung disease.

Previous work has showed that DCAMLK1 is not detectable in the blood of healthy non smoking
individuals. To determine whether smoking and or pulmonary inflammation induce DCAMLK1
expression, the investigators will obtain serum samples from 20 control patients with lung
disease who are seen in the Chest Clinic at the Oklahoma City VAMC. Smoking histories will
be obtained for all participants and DCAMLK1 levels will be correlated with smoking status.

Inclusion Criteria:

- >45 years of age

Exclusion Criteria:

- Unable to provide informed consent

Type of Study:


Study Design:

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

Tumor Markers in Lung Cancer:

Outcome Description:

DCAMLK-1LK-1 levels will be measured in the blood of patients with Lung Cancer and compared to that of controls with other lung diseases.

Outcome Time Frame:

6 months

Safety Issue:


Principal Investigator

Kellie Jones, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Oklahoma


United States: Institutional Review Board

Study ID:




Start Date:

December 2011

Completion Date:

July 2012

Related Keywords:

  • Lung Cancer
  • Smoking
  • lung cancer
  • smoking
  • Lung Neoplasms
  • Smoking



VAMC-OKC Oklahoma City, Oklahoma  73104